Oechsner, M <br/><br/>
COMT-inhibition increases serum levels of dihydroxyphenylacetic acid (DOPAC) in patients with advanced Parkinson's disease.  [electronic resource] 

 -  Journal of neural transmission (Vienna, Austria : 1996)  2002 
 - 69-75 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>0300-9564 
<br/><br/><label>Standard No.: </label>10.1007/s702-002-8237-z  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>3,4-Dihydroxyphenylacetic Acid--blood<br/>Aged<br/>Aged, 80 and over<br/>Antiparkinson Agents--therapeutic use<br/>Benzophenones--therapeutic use<br/>Catechol O-Methyltransferase Inhibitors<br/>Dihydroxyphenylalanine--analogs & derivatives<br/>Disease Progression<br/>Dose-Response Relationship, Drug<br/>Female<br/>Homovanillic Acid--blood<br/>Humans<br/>Levodopa--administration & dosage<br/>Male<br/>Middle Aged<br/>Nitrophenols<br/>Parkinson Disease--blood<br/>Tolcapone<br/>Tyrosine--analogs & derivatives